Actionable news
All posts from Actionable news
Actionable news in SRPT: Sarepta Therapeutics, Inc.,

Why Sarepta Therapeutics Plunged After FDA Approval

After a coveted FDA approval for its drug, eteplirsen, used for treating DMD (Duchenne muscular dystrophy), shares of Sarepta Therapeutics, Inc. (SRPT) are slumping. The company issued a stock sale worth $225 million, through a 5.02 million share sale at $59.75.